Affordable Access

deepdyve-link
Publisher Website

Biological therapy of psoriasis.

Authors
Type
Published Article
Journal
Indian Journal of Dermatology
Publisher
Medknow Publications
Volume
55
Issue
2
Pages
161–161
Identifiers
DOI: 10.4103/0019-5154.62754
Source
maverakislab-ucdavis dermatology-ucdavis
License
Unknown

Abstract

The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF-alpha agents have been associated with a variety of serious and "routine" opportunistic infections.

Report this publication

Statistics

Seen <100 times